ABSTRACT-We investigated the mechanism underlying stimulation of HC03 secretion by the nitric ox ide (NO) synthase inhibitor 1V°-nitro-L-arginine methyl ester (L-NAME) in the gastroduodenal mucosa of anesthetized rats. A chambered stomach (in the presence of omeprazole) or a duodenal loop was perfused with saline, and HCO3 secretion was measured at pH 7.0 by a pH-stat method. Intravenous administration of L-NAME increased gastroduodenal HC03 secretion with a concomitant rise in arterial blood pressure and a decrease in heart rate, and the changes were all antagonized by simultaneous administration of L arginine. Vagotomy had no effect on the increased blood pressure response, but significantly inhibited the decrease of heart rate and increase of HC03_ secretion caused by L-NAME. The HC03 stimulatory action of L-NAME was also inhibited by prior administration of yohimbine or prazosin. These agents alone lowered blood pressure and reduced the magnitude of the blood pressure response caused by L-NAME, leading to inhibition of heart rate changes. When JHC03_ output induced by L-NAME was plotted against dblood pressure change (from basal values) under various conditions, a significant relationship was found between these two factors. These results suggest that L-NAME stimulates gastroduodenal HC03_ secretion in association with the inhibition of endogenous NO production, and this mechanism may be in part mediated by a neural reflex through the vagal efferent nerve, resulting from the pressor response to L NAME.
Nitric oxide (NO), which accounts for the biological actions of endothelium-derived relaxing factor (1) , is now known to be generated in various other cells including the epithelium, macrophages and enteric neurons (2) and mimics the protective action of endogenous prostaglan dins (PGs) in the gastric mucosa (3, 4) . However, we found recently that the NO synthase inhibitor 1V°-nitro-L arginine (L-NAME) markedly stimulated HCO3 secre tion in the gastroduodenal mucosa (5, 6) . Since the HCO3 stimulatory effect of L-NAME was antagonized by simultaneous administration of L-arginine, it may be assumed that this action is associated with the inhibition of endogenous NO production. Yet, the mechanism un derlying the stimulation of HC03_ secretion by L-NAME still remains unclear.
L-NAME causes an elevation of arterial blood pressure at the doses that stimulate HC03_ secretion (6) . In gen eral, the rise in blood pressure is accompanied by a reflex activation of the vagus nerve or by suppression of the sympathetic neuronal tone. Furthermore, since HCO3 secretion is increased by vagal electrical stimulation and inhibited by electrical stimulation of splanchnic nerves (7, 8) , it may be possible to speculate that the HC03 stimu latory action of L-NAME is related to changes in such neuronal activity resulting from elevation of blood pres sure.
In this study, we thus investigated the mechanism un derlying stimulation of gastroduodenal HC03 secretion by L-NAME in rats, mainly in relation to the blood pres sure changes caused by this drug.
MATERIALS AND METHODS

Animals
Male Sprague Dawley rats, weighing 230-250g
(Charles River, Shizuoka), were used. The animals were kept in individual cages with raised mesh bottoms to pre vent coprophagia, and they were deprived of food but al lowed free access to tap water for 18 hr before the experi ments. All studies were carried out using 4 6 animals per group under anesthetized conditions induced by i.p. ad ministration of urethane (1.25 g/kg).
Determination of gastroduodenal HC03 secretion HC03_ secretion was measured in a chambered stomach or a duodenal loop according to the previously published papers (6, 9) . The stomach mounted in an ex vivo chamber or the duodenal loop made between the pyloric ring and the area proximal to the outlet of the com mon bile duct was perfused with saline that was gassed with 100% 02, heated at 371C and kept in a reservoir. HC03 secretion was measured at pH 7.0 by a pH-stat method (Hiranuma Comtite-7, Mito) and by adding 10 mM HCl to the reservior. To unmask HC03 in the stomach, acid secretion was inhibited by omeprazole (60 mg/kg, i.p.). The femoral artery was cannulated, and both arterial blood pressure and heart rate were moni tored with a pressure transducer and polygraph (CASE 7903; San-ei, Tokyo). After basal HC03 secretion had stabilized, L-NAME (5 mg/kg) was administered i.v. as a single injection. L-Arginine (200 mg/kg) was given i.v. 5 min before L-NAME, whereas yohimbine (5 mg/kg) and prazosin (0.5 mg/kg) were given s.c. 30 min before ad ministration of L-NAME. Vagotomy was performed at subdiaphragmatic portion 60 min before administration of L-NAME. In some animals, L-NAME (5 mg/ml) was applied topically to the stomach (2 ml) or the duodenum (0.5 ml) for 15 min, and HC03 secretion was measured before and after the exposure.
Measurement of vascular permeability
To examine the effects of L-NAME on gastric and duodenal mucosal vascular permeability, we used a dye method to measure the extravasated amount of dye as described in a previous paper (10) . The animals were given L-NAME (5 mg/kg) i.v., and were sacrified 1 hr later. In each case, 1 ml of 1076 Evans blue (w/w) was in jected i.v. 30 min before killing. The animals were killed by bleeding from the descending aorta, both the stomach and duodenum (2 cm proximal to the pylorus) were re moved, and the amount of dye that had accumulated in the mucosa in 30 min was measured. The stomach and the duodenum were opened along the greater curvature and along the mesenteric artery, respectively. Then, the mu cosa was scraped off using glass slides and weighed. The extraction of dye was performed according to the modified method described by Katayama et al. (11) . The amount of dye recovered from the mucosa was expressed in tug/ 100 mg tissue.
Preparation of drugs
Drugs used were urethane (Tokyo Kasei, Tokyo); 1VG nitro-L-arginine methyl ester, yohimbine, prazosin, Evans blue (Sigma Chemicals, St. Louis, MO, USA); L-arginine (Wako, Osaka); and omeprazole (Hessle, Mondale, Sweden). Urethane, L-NAME and L-arginine were dis solved in saline, while yohimbine and prazosin were sus pended in saline with a trace of Tween 80 (Wako). Each agent was prepared immediately before use and was given in a volume of 0.1 ml per 100 g body wt. in case of i.v. ad ministration or in a volume of 0.5 ml per 100 g body wt. in the cases of i.p. and s.c. administration. Control animals received saline as the vehicle.
Statistics
Data are presented as the mean ±S.E. from four to six rats per group. Statistical analyses were performed by a two-tailed Dunnett's multiple comparison test, and values of P<0.05 were regarded as significant. The correlation between alkaline secretion and blood pressure responses was assessed by linear-regression analysis. Fig. 1 . Effects of L-NAME on gastric (A) and duodenal (B) HC03 secretion in anesthetized rats under various treatments. L-NAME was given i.v. as a single injection. L-Arginine (200 mg/kg) was given i.v. 5 min before L-NAME. Vagotomy was performed 1 hr before ad ministration of L-NAME. Data are expressed as iHCO3 output obtained for 1 hr and represent the means ±S.E. from 6 rats. Statis tically significant difference at P<0.05, #from the control; *from the group given L-NAME + Saline (5 mg/kg). 
RESULTS
Effects of L-NAME on gastroduodenal HCO3 secretion Under our experimental conditions, the animals spon taneously secreted HC03 at steady rates of 0.2-0.4 iEq/5 min in the gastric mucosa (in the absence of acid secretion) and 0.3-0.5 tsEq/5 min in the duodenal mu cosa, respectively. Intravenous administration of L NAME (5 mg/kg) caused an increase of HCO3_ secretion in both the stomach and duodenum (Fig. 1, A and B ). This dose of L-NAME also caused a marked elevation in arterial blood pressure; the mean blood pressure elevated from 84.3 ± 10.5 mmHg to 146.8 ± 13.5 mmHg, and the heart rate decreased from 382.4± 12.2 beats/min to 321.6± 18.1 beats/min within 5 min. These changes caused by L-NAME were all attenuated when the animals were pretreated with L-arginine (200 mg/kg) (Fig. 2) . Co administration of L-arginine reduced JHCO3 output from 5.9± 1.1 liEq/hr to 1.3±0.6 pEq/hr in the stomach and antagonized the increase in blood pressure and decrease in heart rate caused by L-NAME. In addition, the HC03 stimulatory action of L-NAME was also sig nificantly mitigated by vagotomy; JHC03 output was 2.2--.E0.7 iEq/hr in the stomach and 2.2-L0.7 iEq/hr in the duodenum, the values being equivalent to 35.6% and 26.8% of those induced by L-NAME in the control animals. Of particular interest is the finding that vagotomy did not affect the increased blood pressure response, but totally inhibited the decrease in heart rate caused by L-NAME.
On the other hand, the mucosal application of L NAME (5 mg/ml for 15 min) did not cause any effect on basal rates of HC03 secretion in both the stomach and the duodenum; the HCO3_ output in the stomach was 1.4±0.6 pEq/30 min and 1.2±0.7 ,uEq/30 min (N=4) before and after exposure to L-NAME, respectively. Even in such tissues, the subsequent i.v. administration of L NAME (5 mg/ kg) produced an increase of alkaline secre tion as observed in the normal tissues without exposure to L-NAME. In addition, L-NAME applied topically to the gastric or duodenal mucosa did not cause any change in either blood pressure or heart rate (data not shown).
Effects of yohimbine and prazosin on HC03 stimulatory and blood pressure responses induced by L-NAME Subcutaneous administration of yohimbine (5 mg/kg) or prazosin (0.5 mg/kg) alone did not affect the rates of alkaline secretion in either the stomach or the duodenum. However, the HC03 secretory response to L-NAME (5 mg/kg) was significantly reduced by pretreatment with either of these agents in both the stomach and duodenum (Fig. 3) . In the stomach, JHCO3 output caused by L NAME was reduced to 0.3 ± 0.2 pEq/hr and 0.7-L0.2 pEq/hr in the case of yohimbine and prazosin, respectively, and the inhibition was even greater when compared to that by L-arginine (Fig. 4A) . Similar results were obtained Fig. 3 . Effects of prazosin and yohimbine on gastric (A) and duo denal (B) HC03 response induced by L-NAME in anesthetized rats. L-NAME (5 mg/kg) was given i.v. as a single injection. Prazosin (0.5 mg/kg) or yohimbine (5 mg/kg) was given s.c. 30 min before administration of L-NAME. Data are presented as the means±S.E. of values determined every 5 min from 6 rats. Statistically significant difference at P <0.05, from saline; *from the group given L-NAME alone. 0 Saline, • L-NAME, • L NAME + Yohimbine, A L-NAME + Prazosin. Fig. 4 . Total HC03 secretion (JHC03 output) in the stomach (A) and duodenum (B) induced by L-NAME in anesthetized rats, in the presence of prazosin or yohimbine. L-NAME (5 mg/kg) was given i.v. as a single injection. Prazosin (0.5 mg/kg) or yohimbine (5 mg/kg) was given s.c. 30 min before administration of L-NAME. Values are presented as AHC03 output for 1 hr after administra tion of L-NAME and represent the means±S.E. from 6 rats. *Statistically significant difference from saline , at P<0.05.
in duodenal HC03 secretion; iHCO3 output was 3.4 ± 1.2 REq/hr and 3.2 ± 0.8 pEq/hr, respectively (Fig.  4B) . Both yohimbine and prazosin alone caused a profound decrease in blood pressure (-20 mmHg) with minimal change in heart rate. In the animals pretreated with these alpha-blockers, the subsequent administration of L-NAME caused an increase of blood pressure but did not produce any change in heart rate (Fig. 5) . These agents did not affect the magnitude of the blood pressure response induced by L-NAME, yet the maximal values of blood pressure remained in significantly lower ranges than those in the control animals (146.5±4.6 mmHg); values were 102.3-L10.1 mmHg and 110.3--f:6.8 mmHg for yohimbine and prazosin, respectively.
Relationship between HC03
secretory responses and blood pressure changes When Jblood pressure was calculated from the differ ence between the maximal values obtained after adminis tration of L-NAME and those observed before any treat ment, it is evident that iblood pressure change was sig nificantly reduced by either prazosin or yohimbine as well as L-arginine (Fig. 6A) . Vagotomy did not affect iblood pressure induced by L-NAME, yet completely prevented the decrease of heart rate seen after administration of L NAME (Fig. 6B) . When JHC03 output induced in the stomach and the duodenum by L-NAME was plotted against changes in blood pressure (Jblood pressure from basal values) observed under various treatments, a sig nificant relationship was obtained between these two parameters (Fig. 7) , the correlation coefficient (r) being 0.94 in the stomach and 0.98 in the duodenum.
Effect of L-NAME on mucosal vascular permeability
To investigate the mucosal vascular permeability response to L-NAME, we measured the amount of dye trapped in the gastric and duodenal mucosa (extravascu lar sites) for 30 min after i.v. administration of 1 % Evans blue. In the control animals, the amount of extravasated dye was minimal, the values being 2.05 ± 0.19 pgl 100 mg tissue in the stomach and 1.95±0.21 tcg/100 mg tissue in the duodenum (Fig. 8A) . These values in the stomach were not altered by i.v. administration of L-NAME (5 mg/kg, 1.88±0.08 pg/100 mg tissue), while those in the duodenum were significantly increased to 2.82±0.24 pg/100 mg tissue. The increased vascular permeability caused in the duodenum by L-NAME was significantly an tagonized by co-administration of L-arginine, but was not affected by vagotomy or pretreatment with either prazo sin or yohimbine (Fig. 8B) . Concurrent administration of L-arginine with L-NAME reduced the amount of extrava sated dye to 2.21 ±0.19 ICg/100 mg tissue, which is not sig nificantly different from that (1.95 _L0.21 ICg/ 100 mg tis sue) observed in the control rats that did not receive L NAME treatment. 
DISCUSSION
In the present study, we confirmed our previous finding that intravenous administration of L-NAME caused an in crease of HC03 secretion in the gastroduodenal mucosa with a concomitant rise in blood pressure (5, 6) . Since the increased HCO3 response to L-NAME was significantly mitigated by prior administration of L-arginine but not D arginine, it is considered that stimulation of HCO3_ secre tion by L-NAME is associated with the inhibition of endogenous NO production.
In agreement with the previous finding (5), the effect of L-NAME on HCO3_ secretion was significantly attenuat Fig. 6 . Changes in blood pressure (A) and heart rate (B) after administration of L-NAME in anesthetized rats under various treatments. L-NAME (5 mg/kg) was given i.v. as a single injection. L-Arginine (200 mg/kg) was given i.v. 5 min before L-NAME, whereas yohimbine (5 mg/kg) or prazosin (0.5 mg/kg) was given s.c. 30 min before L-NAME. Vagotomy was performed 1 hr before ad ministration of L-NAME. Data are expressed as maximal changes in blood pressure (dmmHg) and heart rate (%) from basal values observed before any treatment and represent the means ±S.E. from 4-5 rats. *Statistically significant difference from the controls, at P < 0.05. ed by vagotomy. We also reported that the stimulatory action of L-NAME on HC03 secretion was inhibited by atropine as well as indomethacin (6) . Vagal excitation stimulates HC03 as well as acid secretions and increases the release and/or biosynthesis of endogenous PGs in the stomach of various species of animals (7, 12, 13) . These findings together indicate that the mechanism of HC03 secretion in response to L-NAME involves vagal-cholin ergic pathways and is partly mediated by endogenous prostaglandins. As observed in this study, the blood pres sure was markedly and persistently elevated after adminis tration of L-NAME. In general, the rise in blood pressure is accompanied by a reflex activation of the vagal nerve activity (7, 8) . A decrease in heart rate following the in crease of blood pressure caused by L-NAME supports a reflex activation of the vagus nerves. In fact, vagotomy Fig. 7 . A relationship between gastric (A) and duodenal (B) HC03 secretion (iHC03 output) and dblood pressure changes in duced by L-NAME in anesthetized rats. L-NAME (5 mg/kg) was given i.v. as a single injection. L-Arginine (200 mg/kg) was given i.v. 5 min before L-NAME, whereas yohimbine (5 mg/kg) or prazosin (0.5 mg/kg) was given s.c. 30 min before L-NAME. 0 Control, • L-NAME, 0 L-arginine+L-NAME, / Prazosin+L-NAME, A Yohimbine+L-NAME. mitigated both HC03 and heart rate responses induced by L-NAME without affecting the increase of blood pres sure. Thus, it may be possible to speculate that the HC03_ stimulatory action of L-NAME is related to changes in parasympathetic neuronal activity resulting from elevation of blood pressure.
Interestingly, the HC03 response caused by L-NAME was also significantly mitigated by prior administration of alpha-adrenoceptor antagonists such as prazosin or yohimbine. Influences of alpha-adrenoceptor agonists on HC03_ secretion is complex; the alpha,-agonist phenyl ephrine stimulates HC03 secretion in the rat duodenum, whereas the alpha2-agonist clonidine inhibits this secre tion (8, 14) . Norepinephrine inhibits HC03_ secretion even in the isolated stomach in vitro (15) . On the other hand, yohimbine reversed the decrease of HC03_ secre tion caused by clonidine or stimulation of splanchnic Fig. 8 . Effects of L-NAME on vascular permeability in the stomach and duodenum of anesthetized rats (A) and those of various treatments on the increased vascular permeability caused by L-NAME in the duodenum (B). L-NAME (5 mg/kg) was given i.v. as a single injection. L-Arginine (200 mg/kg) was given i.v. 5 min before L-NAME, whereas yohimbine (5 mg/kg) or prazosin (0.5 mg/kg) was given s.c. 30 min before L-NAME. Vagotomy was per formed 1 hr before administration of L-NAME. Data are presented as the amount of extravasated dye (Evans blue) for 30 min and repre sent the means ±S.E. from 6 (A) or 4-6 (B) rats. *Statistically signifi cant difference from saline, at P <0.05.
nerves. In the present study, however, yohimbine sig nificantly inhibited the HC03 secretory response to L NAME, suggesting that the effect is not related to the HCO3 transport process at the epithelial cells. As expect ed, administration of prazosin or yohimbine alone produced a substantial decrease of blood pressure with minimal change in heart rate. Although L-NAME in duced a persistent rise in blood pressure even in the animals pretreated with such alpha-blockers, the maximal values in blood pressure were significantly lower than those in control animals, leading to inhibition of the bradycardic response caused by L-NAME. These results strongly support the hypothesis that L-NAME stimulates HC03 secretion, at least partly mediated by a neural reflex through vagal efferent nerves, resulting from the marked increase in blood pressure. It also seems that for obtaining such HCO3 and bradycardic responses in duced by L-NAME, the blood pressure not only shows a definite increase but also elevates beyond certain levels. We have recently reported that endothelin-1, a potent vasopressor agent, also increased gastric HCO3 secre tion with a marked elevation of blood pressure (6) . On mere speculation, the increase in the vagal nerve tone might lead to changes in acid secrtion and motility as well as HCO3 secretion. Yet, L-NAME does not have any influence on gastric acid secretion, at least in normal stomachs (16) . It is assumed that the sensitivity to vagal nerve stimulation might be different depending upon the cell type responsible for each function. Certainly, further studies would be required to clarify this point.
On the other hand, Kubes (17) and Kubes and Granger (18) reported that the inhibition of endogenous NO production by L-NAME enhanced both the endothelial and epithelial permeability in feline small intestine. There fore, it might be possible that the increase of HCO3 Out put by L-NAME is attributable to leakage of interstitial fluid or plasma into the lumen. In this study, the vascular permeability in the gastric mucosa was not significantly al tered by L-NAME at the dose that caused a marked in crease of HCO3 output and blood pressure, although the vascular permeability in the duodenum was significant ly increased by this agent. However, this increase in the duodenal vascular permeability was not significantly influenced by either prazosin or yohimbine as well as vagotomy, yet such treatments have been demonstrated to inhibit the HCO3 response to L-NAME in this study. Similar findings were reported by Hallgren et al. (19) , who showed that hexamethonium significantly inhibited the HCO3 response induced by N -nitro-L-agrinine with no effect on the increased vascular permeability change. Thus, these findings indicate that the luminal alkaliniza tion induced by L-NAME is not simply due to leakage of HCO3 from the blood. Recently, Hallgren and Nylander (20) demonstrated that L-NAME caused an increase of both alkaline secre tion and luminal pressure in the rat duodenum, and these effects were prevented by papaverine as well as hexametho nium. They hypothesized that the luminal alkalinization by L-NAME in the duodenum may be due to the neural reflex resulting from the increase of luminal pressure through mechano-receptors. In our study, however, the stomach was mounted in a chamber and superfused at a constant flow rate with saline. Under these conditions the pressure of the stomach lumen may be relatively constant, yet L-NAME caused a marked increase of luminal alkalinization as observed in the duodenal loop. In addi tion, we observed that L-NAME applied topically to the mucosa did not have any effect on the basal rates of HC03 secretion in both the stomach and duodenum. There fore, it seems unlikely that stimulation by L-NAME of HC03 secretion is brought about by an increase of the luminal pressure in these tissues.
The current data demonstrated that the selective block ade of NO synthase by L-NAME increased HC03 secre tion from the gastroduodenal mucosa of anesthetized rats. This action appears to be associated with inhibition of NO biosynthesis, and this process may be partly mediated by a neural reflex through vagal efferent nerves, resulting from the marked increase of blood pressure. This effect is inhibited by L-arginine at the vascular level and also mitigated by alpha-blockers, probably by decreasing the blood pressure response to L-NAME. Vagotomy blocks the vagal efferent pathway to stimulate HC03 secretion under such conditions. Certainly, since we have reported that the exogenous NO donor nitroprus side not only antagonized the stimulatory effect of L NAME on HC03 secretion but also caused a dose dependent reduction in the HC03 response induced by 16,16-dimethyl PGE2 (6, 21) , it is possible that the HC03 stimulatory effect of L-NAME may be partly ac counted for by removal of the negative influence of endo genous NO on this secretion. Although NO is a stimulator of soluble guanylate cyclase, leading to accumulation of cyclic GMP (2), it remains unknown at present whether L-NAME affects HC03 secretion directly through changes in the guanylate cyclase/cyclic GMP system.
